- Home
- CELU vs XGN Comparison
CELU vs XGN Comparison
Compare CELU & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | XGN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 110.7M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CELU | XGN |
|---|---|---|
| Price | $0.86 | $7.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | ★ $8.86 |
| AVG Volume (30 Days) | 38.2K | ★ 438.6K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,550,000.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | $76.00 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $2.59 |
| 52 Week High | $4.01 | $12.23 |
Technical Indicators
Market Signals| Indicator | CELU | XGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 72.35 |
| Support Level | N/A | $4.08 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.36 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 80.91 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.